Difference between revisions of "Mechlorethamine (Mustargen)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (18 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Nitrogen mustard, alkylator. Crosslinks DNA, interfering with cell replication.<ref name="insert">[http://patient.cancerconsultants.com/druginserts/Mechlorethamine.pdf Mechlorethamine (Mustargen) package insert]</ref><ref>[ | + | Class/mechanism: Nitrogen mustard, alkylator. Crosslinks DNA, interfering with cell replication.<ref name="insert">[http://patient.cancerconsultants.com/druginserts/Mechlorethamine.pdf Mechlorethamine (Mustargen) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/mechlorethamine.pdf Mechlorethamine (Mustargen) package insert (locally hosted backup)]</ref> |
| − | <br>Route: IV, intracavitary | + | <br>Route: IV, intracavitary, topical |
<br>Extravasation: [[vesicant]] | <br>Extravasation: [[vesicant]] | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Hodgkin lymphoma]] | + | *[[HIV-associated lymphoma]] |
| + | *[[Classical Hodgkin lymphoma]] | ||
| + | |||
| + | ==Diseases for which it was used== | ||
| + | *[[Diffuse large B-cell lymphoma - historical|Diffuse large B-cell lymphoma]] | ||
| + | *[[Follicular lymphoma - historical|Follicular lymphoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 14: | Line 19: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | * 1949-03-15: Initial FDA approval ('''This is the first chemotherapy agent ever approved''') |
| − | * | + | * 2004-02-09 (only label available at Drugs @ FDA): |
# "Administered intravenously, is indicated for the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma." | # "Administered intravenously, is indicated for the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma." | ||
| − | # "Administered intrapleurally, intraperitoneally, or intrapericardially, is indicated for the palliative treatment of metastatic carcinoma resulting in effusion." | + | # "Administered intrapleurally, intraperitoneally, or intrapericardially, is indicated for the palliative treatment of metastatic carcinoma resulting in effusion." |
| − | + | ||
==Also known as== | ==Also known as== | ||
| − | + | *'''Generic name:''' chlormethine, nitrogen mustard | |
| + | *'''Brand names:''' Ledaga, Mustargen, Mustine | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
| − | [[Category: | + | [[Category:Intravenous medications]] |
| − | [[Category: | + | [[Category:Intracavitary medications]] |
| − | [[Category: | + | [[Category:Topical medications]] |
| − | [[Category:Vesicant | + | [[Category:Vesicant]] |
[[Category:Alkylating agents]] | [[Category:Alkylating agents]] | ||
[[Category:Nitrogen mustards]] | [[Category:Nitrogen mustards]] | ||
| − | [[Category:Hodgkin lymphoma medications]] | + | [[Category:HIV-associated lymphoma medications]] |
| + | [[Category:Classical Hodgkin lymphoma medications]] | ||
| + | |||
| + | [[Category:Diffuse large B-cell lymphoma medications (historic)]] | ||
| + | [[Category:Follicular lymphoma medications (historic)]] | ||
| − | [[Category: | + | [[Category:FDA approved in 1949]] |
Latest revision as of 01:06, 29 June 2024
General information
Class/mechanism: Nitrogen mustard, alkylator. Crosslinks DNA, interfering with cell replication.[1][2]
Route: IV, intracavitary, topical
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is used
Diseases for which it was used
Patient drug information
- Mechlorethamine (Mustargen) patient drug information (Chemocare)[3]
- Mechlorethamine (Mustargen) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1949-03-15: Initial FDA approval (This is the first chemotherapy agent ever approved)
- 2004-02-09 (only label available at Drugs @ FDA):
- "Administered intravenously, is indicated for the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma."
- "Administered intrapleurally, intraperitoneally, or intrapericardially, is indicated for the palliative treatment of metastatic carcinoma resulting in effusion."
Also known as
- Generic name: chlormethine, nitrogen mustard
- Brand names: Ledaga, Mustargen, Mustine
References
Categories:
- Drugs
- Intravenous medications
- Intracavitary medications
- Topical medications
- Vesicant
- Alkylating agents
- Nitrogen mustards
- HIV-associated lymphoma medications
- Classical Hodgkin lymphoma medications
- Diffuse large B-cell lymphoma medications (historic)
- Follicular lymphoma medications (historic)
- FDA approved in 1949